NPHLA Daily
NPHLA Daily
Friday, October 30, 2026 · 4-minute read
Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.
Top development today
What changed today in Metabolic: 1 new study
NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in Expert opinion on pharmacotherapy: “Switching between semaglutide and tirzepatide in obesity Management: an expert-consensus framework for approximate clinical Efficacy-matched switching doses”.
Metabolic signal
What changed today in Metabolic: 1 trial update
NPHLA tracked 1 new official record on this desk today: 1 trial update. First: Trial status changed to “Recruiting”: FutureShape Family
Aesthetics & Longevity signal
What changed today in Aesthetics & Longevity: 1 new study
NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in Journal of drug targeting: “Vitamin E Nanoemulsion Loaded Exosomes Attenuates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting NLRP3-Mediated Pyroptosis and Fibrotic Signaling”.
AI & Technology signal
What changed today in AI & Technology: 1 new study
NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in Annals of emergency medicine: “Ambient Artificial Intelligence Scribe Use and Objective Documentation Effort Among Emergency Physicians”.
One thing worth watching
Comments close: Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information…
November 26, 2026 — verified from the Federal Register comments_close_on.
5 things to know
- What changed today in Metabolic: 1 new study
- What changed today in Metabolic: 1 trial update
- What changed today in Aesthetics & Longevity: 1 new study
- What changed today in AI & Technology: 1 new study
- Switching between semaglutide and tirzepatide in obesity Management: an expert-consensus framework for approximate clinical Efficacy-matched switching doses (Expert opinion on pharmacotherapy)
Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.